Skip Nav Destination
Issues
1 December 2015
-
Cover Image
Cover Image
The cover shows a crystal structure of EGFR protein with afatinib, one of the second generation EGFR tyrosine kinase inhibitors. Afatinib forms a covalent bond with cysteine 797. For details, see the article by Kobayashi and colleagues on page 5305 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
20th Anniversary Commentary
CCR Translations
CCR New Strategies
CCR Perspectives in Drug Approval
FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer
Abhilasha Nair; Steven J. Lemery; Jun Yang; Anshu Marathe; Liang Zhao; Hong Zhao; Xiaoping Jiang; Kun He; Gaetan Ladouceur; Amit K. Mitra; Liang Zhou; Emily Fox; Stephanie Aungst; Whitney Helms; Patricia Keegan; Richard Pazdur
Molecular Pathways
Cancer Therapy: Clinical
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Ravi K. Amaravadi; Kathryn E. Hamilton; Xiaohong Ma; Shengfu Piao; Armando Del Portillo; Katherine L. Nathanson; Matteo S. Carlino; Georgina V. Long; Igor Puzanov; Xiaowei Xu; Jennifer J.D. Morrissette; Kenneth Y. Tsai; Keith T. Flaherty; Jeffrey A. Sosman; Grant R. Goodman; Grant A. McArthur; Anil K. Rustgi; David C. Metz; Lynn M. Schuchter; Paul B. Chapman; Antonia R. Sepulveda
Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer
Yasuo Iwamoto; Tetsuya Mitsudomi; Kazuko Sakai; Takeharu Yamanaka; Hiroshige Yoshioka; Makoto Takahama; Masahiro Yoshimura; Ichiro Yoshino; Masayuki Takeda; Shunichi Sugawara; Tomoya Kawaguchi; Toshiaki Takahashi; Mitsunori Ohta; Yukito Ichinose; Shinji Atagi; Morihito Okada; Hideo Saka; Kazuhiko Nakagawa; Yoichi Nakanishi; Kazuto Nishio
Personalized Medicine and Imaging
Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non–Small Cell Lung Cancer Patients (SAKK 19/05 trial)
Anca Franzini; Florent Baty; Ina I. Macovei; Oliver Dürr; Cornelia Droege; Daniel Betticher; Bogdan D. Grigoriu; Dirk Klingbiel; Francesco Zappa; Martin H. Brutsche
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Sharon E. Johnatty; on behalf of the Australian Ovarian Cancer Study Group; Jonathan P. Tyrer; on behalf of the Australian Ovarian Cancer Study Group; Siddhartha Kar; on behalf of the Australian Ovarian Cancer Study Group; Jonathan Beesley; on behalf of the Australian Ovarian Cancer Study Group; Yi Lu; on behalf of the Australian Ovarian Cancer Study Group; Bo Gao; on behalf of the Australian Ovarian Cancer Study Group; Peter A. Fasching; on behalf of the Australian Ovarian Cancer Study Group; Alexander Hein; on behalf of the Australian Ovarian Cancer Study Group; Arif B. Ekici; on behalf of the Australian Ovarian Cancer Study Group; Matthias W. Beckmann; on behalf of the Australian Ovarian Cancer Study Group; Diether Lambrechts; on behalf of the Australian Ovarian Cancer Study Group; Els Van Nieuwenhuysen; on behalf of the Australian Ovarian Cancer Study Group; Ignace Vergote; on behalf of the Australian Ovarian Cancer Study Group; Sandrina Lambrechts; on behalf of the Australian Ovarian Cancer Study Group; Mary Anne Rossing; on behalf of the Australian Ovarian Cancer Study Group; Jennifer A. Doherty; on behalf of the Australian Ovarian Cancer Study Group; Jenny Chang-Claude; on behalf of the Australian Ovarian Cancer Study Group; Francesmary Modugno; on behalf of the Australian Ovarian Cancer Study Group; Roberta B. Ness; on behalf of the Australian Ovarian Cancer Study Group; Kirsten B. Moysich; on behalf of the Australian Ovarian Cancer Study Group; Douglas A. Levine; on behalf of the Australian Ovarian Cancer Study Group; Lambertus A. Kiemeney; on behalf of the Australian Ovarian Cancer Study Group; Leon F.A.G. Massuger; on behalf of the Australian Ovarian Cancer Study Group; Jacek Gronwald; on behalf of the Australian Ovarian Cancer Study Group; Jan Lubiński; on behalf of the Australian Ovarian Cancer Study Group; Anna Jakubowska; on behalf of the Australian Ovarian Cancer Study Group; Cezary Cybulski; on behalf of the Australian Ovarian Cancer Study Group; Louise Brinton; on behalf of the Australian Ovarian Cancer Study Group; Jolanta Lissowska; on behalf of the Australian Ovarian Cancer Study Group; Nicolas Wentzensen; on behalf of the Australian Ovarian Cancer Study Group; Honglin Song; on behalf of the Australian Ovarian Cancer Study Group; Valerie Rhenius; on behalf of the Australian Ovarian Cancer Study Group; Ian Campbell; on behalf of the Australian Ovarian Cancer Study Group; Diana Eccles; on behalf of the Australian Ovarian Cancer Study Group; Weiva Sieh; on behalf of the Australian Ovarian Cancer Study Group; Alice S. Whittemore; on behalf of the Australian Ovarian Cancer Study Group; Valerie McGuire; on behalf of the Australian Ovarian Cancer Study Group; Joseph H. Rothstein; on behalf of the Australian Ovarian Cancer Study Group; Rebecca Sutphen; on behalf of the Australian Ovarian Cancer Study Group; Hoda Anton-Culver; on behalf of the Australian Ovarian Cancer Study Group; Argyrios Ziogas; on behalf of the Australian Ovarian Cancer Study Group; Simon A. Gayther; on behalf of the Australian Ovarian Cancer Study Group; Aleksandra Gentry-Maharaj; on behalf of the Australian Ovarian Cancer Study Group; Usha Menon; on behalf of the Australian Ovarian Cancer Study Group; Susan J. Ramus; on behalf of the Australian Ovarian Cancer Study Group; Celeste L. Pearce; on behalf of the Australian Ovarian Cancer Study Group; Malcolm C. Pike; on behalf of the Australian Ovarian Cancer Study Group; Daniel O. Stram; on behalf of the Australian Ovarian Cancer Study Group; Anna H. Wu; on behalf of the Australian Ovarian Cancer Study Group; Jolanta Kupryjanczyk; on behalf of the Australian Ovarian Cancer Study Group; Agnieszka Dansonka-Mieszkowska; on behalf of the Australian Ovarian Cancer Study Group; Iwona K. Rzepecka; on behalf of the Australian Ovarian Cancer Study Group; Beata Spiewankiewicz; on behalf of the Australian Ovarian Cancer Study Group; Marc T. Goodman; on behalf of the Australian Ovarian Cancer Study Group; Lynne R. Wilkens; on behalf of the Australian Ovarian Cancer Study Group; Michael E. Carney; on behalf of the Australian Ovarian Cancer Study Group; Pamela J. Thompson; on behalf of the Australian Ovarian Cancer Study Group; Florian Heitz; on behalf of the Australian Ovarian Cancer Study Group; Andreas du Bois; on behalf of the Australian Ovarian Cancer Study Group; Ira Schwaab; on behalf of the Australian Ovarian Cancer Study Group; Philipp Harter; on behalf of the Australian Ovarian Cancer Study Group; Jacobus Pisterer; on behalf of the Australian Ovarian Cancer Study Group; Peter Hillemanns; on behalf of the Australian Ovarian Cancer Study Group; on behalf of the AGO Study Group; Beth Y. Karlan; on behalf of the Australian Ovarian Cancer Study Group; Christine Walsh; on behalf of the Australian Ovarian Cancer Study Group; Jenny Lester; on behalf of the Australian Ovarian Cancer Study Group; Sandra Orsulic; on behalf of the Australian Ovarian Cancer Study Group; Stacey J. Winham; on behalf of the Australian Ovarian Cancer Study Group; Madalene Earp; on behalf of the Australian Ovarian Cancer Study Group; Melissa C. Larson; on behalf of the Australian Ovarian Cancer Study Group; Zachary C. Fogarty; on behalf of the Australian Ovarian Cancer Study Group; Estrid Høgdall; on behalf of the Australian Ovarian Cancer Study Group; Allan Jensen; on behalf of the Australian Ovarian Cancer Study Group; Susanne Kruger Kjaer; on behalf of the Australian Ovarian Cancer Study Group; Brooke L. Fridley; on behalf of the Australian Ovarian Cancer Study Group; Julie M. Cunningham; on behalf of the Australian Ovarian Cancer Study Group; Robert A. Vierkant; on behalf of the Australian Ovarian Cancer Study Group; Joellen M. Schildkraut; on behalf of the Australian Ovarian Cancer Study Group; Edwin S. Iversen; on behalf of the Australian Ovarian Cancer Study Group; Kathryn L. Terry; on behalf of the Australian Ovarian Cancer Study Group; Daniel W. Cramer; on behalf of the Australian Ovarian Cancer Study Group; Elisa V. Bandera; on behalf of the Australian Ovarian Cancer Study Group; Irene Orlow; on behalf of the Australian Ovarian Cancer Study Group; Tanja Pejovic; on behalf of the Australian Ovarian Cancer Study Group; Yukie Bean; on behalf of the Australian Ovarian Cancer Study Group; Claus Høgdall; on behalf of the Australian Ovarian Cancer Study Group; Lene Lundvall; on behalf of the Australian Ovarian Cancer Study Group; Ian McNeish; on behalf of the Australian Ovarian Cancer Study Group; James Paul; on behalf of the Australian Ovarian Cancer Study Group; Karen Carty; on behalf of the Australian Ovarian Cancer Study Group; Nadeem Siddiqui; on behalf of the Australian Ovarian Cancer Study Group; Rosalind Glasspool; on behalf of the Australian Ovarian Cancer Study Group; Thomas Sellers; on behalf of the Australian Ovarian Cancer Study Group; Catherine Kennedy; on behalf of the Australian Ovarian Cancer Study Group; Yoke-Eng Chiew; on behalf of the Australian Ovarian Cancer Study Group; Andrew Berchuck; on behalf of the Australian Ovarian Cancer Study Group; Stuart MacGregor; on behalf of the Australian Ovarian Cancer Study Group; Paul D.P. Pharoah; on behalf of the Australian Ovarian Cancer Study Group; Ellen L. Goode; on behalf of the Australian Ovarian Cancer Study Group; Anna deFazio; on behalf of the Australian Ovarian Cancer Study Group; Penelope M. Webb; on behalf of the Australian Ovarian Cancer Study Group; Georgia Chenevix-Trench; on behalf of the Australian Ovarian Cancer Study Group
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar; Joseph A. O'Donoghue; Jeremy C. Durack; Serge K. Lyashchenko; Sarah M. Cheal; Volkan Beylergil; Robert A. Lefkowitz; Jorge A. Carrasquillo; Danny F. Martinez; Alex Mak Fung; Stephen B. Solomon; Mithat Gönen; Glenn Heller; Massimo Loda; David M. Nanus; Scott T. Tagawa; Jarett L. Feldman; Joseph R. Osborne; Jason S. Lewis; Victor E. Reuter; Wolfgang A. Weber; Neil H. Bander; Howard I. Scher; Steven M. Larson; Michael J. Morris
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
Frank A. Sinicrope; for the Alliance for Clinical Trials in Oncology; Michelle R. Mahoney; for the Alliance for Clinical Trials in Oncology; Harry H. Yoon; for the Alliance for Clinical Trials in Oncology; Thomas C. Smyrk; for the Alliance for Clinical Trials in Oncology; Stephen N. Thibodeau; for the Alliance for Clinical Trials in Oncology; Richard M. Goldberg; for the Alliance for Clinical Trials in Oncology; Garth D. Nelson; for the Alliance for Clinical Trials in Oncology; Daniel J. Sargent; for the Alliance for Clinical Trials in Oncology; Steven R. Alberts; for the Alliance for Clinical Trials in Oncology
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Yoshihisa Kobayashi; Yosuke Togashi; Yasushi Yatabe; Hiroshi Mizuuchi; Park Jangchul; Chiaki Kondo; Masaki Shimoji; Katsuaki Sato; Kenichi Suda; Kenji Tomizawa; Toshiki Takemoto; Toyoaki Hida; Kazuto Nishio; Tetsuya Mitsudomi
Cancer Therapy: Preclinical
Author Choice
Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma
Dominique Tierny; François Serres; Zacharie Segaoula; Ingrid Bemelmans; Emmanuel Bouchaert; Aurélie Pétain; Viviane Brel; Stéphane Couffin; Thierry Marchal; Laurent Nguyen; Xavier Thuru; Pierre Ferré; Nicolas Guilbaud; Bruno Gomes
Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells
Chitra Venugopal; Robin Hallett; Parvez Vora; Branavan Manoranjan; Sujeivan Mahendram; Maleeha A. Qazi; Nicole McFarlane; Minomi Subapanditha; Sara M. Nolte; Mohini Singh; David Bakhshinyan; Neha Garg; Thusyanth Vijayakumar; Boleslaw Lach; John P. Provias; Kesava Reddy; Naresh K. Murty; Bradley W. Doble; Mickie Bhatia; John A. Hassell; Sheila K. Singh
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
Yan Liu; Oriana E. Hawkins; Anna E. Vilgelm; Jeffrey S. Pawlikowski; Jeffrey A. Ecsedy; Jeffrey A. Sosman; Mark C. Kelley; Ann Richmond
Biology of Human Tumors
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway
Hong Lou; Guillermo Villagran; Joseph F. Boland; Kate M. Im; Sarita Polo; Weiyin Zhou; Ushie Odey; Eligia Juárez-Torres; Ingrid Medina-Martínez; Edgar Roman-Basaure; Jason Mitchell; David Roberson; Julie Sawitzke; Lisa Garland; Maria Rodríguez-Herrera; David Wells; Jennifer Troyer; Francisco Castillo Pinto; Sara Bass; Xijun Zhang; Miriam Castillo; Bert Gold; Hesler Morales; Meredith Yeager; Jaime Berumen; Enrique Alvirez; Eduardo Gharzouzi; Michael Dean
Author Choice
Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
Jean McBryan; Ailís Fagan; Damian McCartan; Fiona T. Bane; Damir Varešlija; Sinéad Cocchiglia; Christopher Byrne; Jarlath Bolger; Marie McIlroy; Lance Hudson; Paul Tibbitts; Peadar Ó Gaora; Arnold D. Hill; Leonie S. Young
Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer
Se-Ra Lee; Yun-Gil Roh; Seon-Kyu Kim; Ju-Seog Lee; So-Young Seol; Hyun-Hee Lee; Won-Tae Kim; Wun-Jae Kim; Jeonghoon Heo; Hee-Jae Cha; Tae-Hong Kang; Jin Woong Chung; In-Sun Chu; Sun-Hee Leem
Letter to the Editor
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.